Grant RDF
pages:- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- more...
- A Phase III, Open Label Single Arm Study of Tenecteplase Forrestoration of Function in Dysfunctional Central Venous.....
- A Phase III, Open Label, Randomized Study of Azd9291 Versus Platinum-Based Doublet Chemotherapy for Patients With ...
- A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment Versus No Further.....
- A Phase III, Prospective, Multicenter, Open-Label Extension Study to Assess the Longer Term Safety and Efficacy of Repea
- A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 ...
- A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-Viv
- A Phase III, Randomized, Double-Blind, Multi Center, Placebocontrolled Safety Study and Efficacy Study of Spd465 in Adhd
- A Phase III, Randomized, Double-Blind, Multi-Center Clinical Trial Comparing the Safety and Efficacy of Veronate Versus
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Examining the Efficacy and Safety of Altu-135 Treatment
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Safety
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induciton and Maintenance Treatement for Patients with Moderately to Severely Active Crohn’s Disease
- A Phase III, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Albumin Interferon Alfa-2a (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1
- A Phase III, Randomized, Open-Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine...
- A Phase III, Randomized, Parell Group, Multi-Centre Study in Recurrent Glioblastoma Subjects to Compare the Efficacy....
- A Phase III, Three-Week, Multicenter, Randomized. Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Extended-Release Carbamazepine in the Treatment of Bipolar Disorder
- A Phase III,Multi-Ctr Randomized,Dble-Blind,Placebo-Cntrlledtrial of the Ex-Vivo Treatment with Cgt0033 of Peropheral...
- A Phase III,Multi-Ctr,Open-Lbl,Randmzed Study to Compare Theoverall Survival and Safety of Bi-Weekly Intratumoral Admin Of
- A Phase III...Study of Oral Cci-779 Admin in Combo with Letrozole vs Letrozole Alone As First Line Hormonal Thera...
- A Phase Iiib Multicentre, Open Label Induction and Double Blind Comparison of Two Maintenance Schedules Evaluating......
- A Phase Iiib, Multicentre, Randomized, Double-Blind, Placebocontrolled Study Evaluating the Efficacy & Safety of Dysport
- A Phase Iiib, Prospective, Multicentre, Open-Label Extensionstudy to Assess Long Term Safety and Effectiveness Of.......
- A Phase Iiib, Randomized, Open Label Study of the Safety, Efficacy and Tolerability of Switching to a Fixed Dose......
- A Phase IIIb/Iv, Open-Labeled, Multi-Center Trial to Evaluate the Safety, Tolerability, and Efficacy of Hiv-1....
- A Phase Ill, International, Multi-Center, Randomized, Doubleblind, Placebo-Controlled, Event Driven Study to Compare . .
- A Phase IV Prospective Single Arm Open Label Study to Measure Outcomes in Patients With Pulmonary Arterial........
- A Phase IV Randomized Multi-Centre Open Label Comparison of Platelet Inhibition Following Loading Doses of Ticagrelor...
- A Phase IV Randomized, Double-Blind, Active And..Pramipexolein Patients With Idiopathic Restless Leg Syndrome
- A Phase Iv, Non-Randomized, Open-Label Trial Evaluating the Safety of 625 Mg Formulation of Virace......
- A Phase Iv, Open-Label, Multictr Study of Treatment with Trizivir (Abacavir 300mg/Lamivudine A50mg/Zidovudine 300mg)